- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05209568
Immune Responses to Gluten
January 11, 2024 updated by: Jocelyn Silvester, Boston Children's Hospital
Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multi-site open-label single dose gluten challenge study.
Participants will provide a blood sample for measurement of cytokines before and 4 hours after eating gluten powder.
Study Type
Interventional
Enrollment (Estimated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jocelyn A Silvester, MD, PhD
- Phone Number: 617-355-8880
- Email: jocelyn.silvester@childrens.harvard.edu
Study Contact Backup
- Name: Marisa Stahl, MD, MSCS
- Email: marisa.stahl@childrenscolorado.org
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Marisa Stahl, MD, MSCS
- Phone Number: 720-777-2484
- Email: marisa.stahl@childrenscolorado.org
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Jocelyn A Silvester, MD, PhD
- Phone Number: 617-355-8880
- Email: jocelyn.silvester@childrens.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 101 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- On a gluten-free diet for ≥ 4 weeks
- Willing to consume gluten for research
- For the celiac disease arm, diagnosis confirmed by serology and/or histology
Exclusion Criteria:
- Pregnancy
- Wheat allergy
- Type 1 diabetes
- BMI z-score < -2
- History of more than minimal symptoms following gluten exposure on a gluten-free diet
- Comorbid condition that in the opinion of the investigator would interfere with study participation or would confound study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Celiac Disease
Individuals with a confirmed diagnosis of celiac disease based on serology and/or histology
|
Single oral dose of gluten powder
|
Experimental: Healthy Controls
Individuals without a diagnosis of celiac disease
|
Single oral dose of gluten powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in serum interleukin-2 (IL-2) level from baseline to 4 hours after a single oral dose of gluten
Time Frame: Baseline, 4 hours
|
To determine the change in serum IL-2 level from baseline after a single oral dose of gluten
|
Baseline, 4 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jocelyn A Silvester, MD, PhD, Boston Children's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci Adv. 2019 Aug 7;5(8):eaaw7756. doi: 10.1126/sciadv.aaw7756. eCollection 2019 Aug.
- Goel G, Daveson AJM, Hooi CE, Tye-Din JA, Wang S, Szymczak E, Williams LJ, Dzuris JL, Neff KM, Truitt KE, Anderson RP. Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clin Exp Immunol. 2020 Jan;199(1):68-78. doi: 10.1111/cei.13369. Epub 2019 Oct 1.
- Tye-Din JA, Daveson AJM, Ee HC, Goel G, MacDougall J, Acaster S, Goldstein KE, Dzuris JL, Neff KM, Truitt KE, Anderson RP. Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Aliment Pharmacol Ther. 2019 Oct;50(8):901-910. doi: 10.1111/apt.15477. Epub 2019 Sep 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2023
Primary Completion (Estimated)
September 30, 2028
Study Completion (Estimated)
September 30, 2029
Study Registration Dates
First Submitted
January 13, 2022
First Submitted That Met QC Criteria
January 13, 2022
First Posted (Actual)
January 26, 2022
Study Record Updates
Last Update Posted (Estimated)
January 15, 2024
Last Update Submitted That Met QC Criteria
January 11, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P00039708
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant demographic and cytokine data collected during the trial, after deidentification.
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following article publication.
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Diseases
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Campus Bio-Medico UniversityRecruitingGastrointestinal Cancer | Gastrointestinal Hemorrhage | Gastrointestinal Lesions | Gastrointestinal Injury | Gastrointestinal Perforation | Gastrointestinal UlcerItaly
-
Massachusetts General HospitalEnrolling by invitationGastrointestinal Dysfunction | Gastrointestinal DiseaseUnited States
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Jiangxi University of Traditional Chinese MedicineThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsCompletedGastrointestinal DiseaseChina
-
Indiana UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingFunctional Gastrointestinal DisordersUnited States
-
Beth Israel Deaconess Medical CenterCompleted
-
Nationwide Children's HospitalCompletedFunctional Gastrointestinal DisordersUnited States
Clinical Trials on Gluten Powder
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden
-
Regeneron PharmaceuticalsRecruiting
-
Merck Sharp & Dohme LLCCompleted
-
Massachusetts General HospitalTerminated
-
University of Southern DenmarkOdense University Hospital; University Hospital Bispebjerg and Frederiksberg; Hospital of Southern Jutland and other collaboratorsNot yet recruitingInflammatory Bowel Diseases | Ulcerative ColitisDenmark
-
University Hospital, Clermont-FerrandCentre de Recherche en Nutrition Humaine d'Auvergne; Institut National de Recherche... and other collaboratorsCompleted
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; University of Skövde; Ekhaga foundationRecruitingDiabetes | Celiac Disease | Metabolic Disease | AutoimmunitySweden
-
Università degli Studi di BresciaUnknownNon Celiac Gluten SensitivityItaly
-
University of CopenhagenTechnical University of DenmarkCompletedMetabolic Diseases | Injury of Gastrointestinal TractDenmark
-
TakedaActive, not recruitingCeliac DiseaseUnited States, Belgium, Poland, Italy, Canada, United Kingdom, France, Spain